InsiderTrades.com logo

ESLA Insider Trading

Insider Ownership Percentage: 55.10%
Insider Buying (Last 12 Months): $2,594.00
Insider Selling (Last 12 Months): $0.00

Estrella Immunopharma Insider Trading History Chart

This chart shows the insider buying and selling history at Estrella Immunopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Estrella Immunopharma Share Price & Price History

Current Price: $1.47
Price Change: ▼ Price Decrease of -0.06 (-3.92%)
As of 04/29/2026 05:00 PM ET

This chart shows the closing price history over time for ESLA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Estrella Immunopharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/7/2025Jiandong XuCFOBuy1,000$1.33$1,330.00265,488View SEC Filing Icon  
9/22/2025Jiandong XuCFOBuy1,000$1.16$1,160.0016,700View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Estrella Immunopharma (NASDAQ:ESLA)

0.35% of Estrella Immunopharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ESLA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Estrella Immunopharma Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/18/2026XTX Topco Ltd49,472$77K0.0%+376.9%0.131%Search for SEC Filing on Google Icon
2/18/2026Quadrature Capital Ltd27,781$43K0.0%N/A0.074%Search for SEC Filing on Google Icon
2/13/2026Marshall Wace LLP56,236$88K0.0%N/A0.149%Search for SEC Filing on Google Icon
2/13/2026State Street Corp43,252$67K0.0%+93.5%0.115%Search for SEC Filing on Google Icon
2/12/2026Renaissance Technologies LLC122,468$0.19M0.0%+1,045.7%0.324%Search for SEC Filing on Google Icon
2/9/2026Geode Capital Management LLC109,808$0.17M0.0%+8.2%0.291%Search for SEC Filing on Google Icon
2/12/2025Geode Capital Management LLC93,418$0.11M0.0%+22.0%0.258%Search for SEC Filing on Google Icon
2/13/2024ATW Spac Management LLC40,000$44K0.1%N/A0.114%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Estrella Immunopharma logo
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Read More on Estrella Immunopharma

Today's Range

Now: $1.47
Low: $1.44
High: $1.56

50 Day Range

MA: $1.33
Low: $0.97
High: $1.92

52 Week Range

Now: $1.47
Low: $0.78
High: $3.15

Volume

22,604 shs

Average Volume

174,452 shs

Market Capitalization

$62.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58

Who are the company insiders with the largest holdings of Estrella Immunopharma?

Estrella Immunopharma's top insider investors include:
  1. Jiandong Xu (CFO)
Learn More about top insider investors at Estrella Immunopharma.